The Finnish company, FIT Biotech, specializes in developing gene-based treatments, including antibody therapies for cancer immunotherapy and DNA vaccines for infectious diseases like HIV. Their innovative GTU technology allows for the production of antibodies in the human body, eliminating the need for industrially manufactured antibodies. FIT Biotech generates revenue through the sale of services related to their HIV vaccine.